Account
Articles
28.04.2022
Regulators are giving early access to medicines, b...

Introduction Early Access Programs (EAPs) help to give people with life threatening or seriously deb...

Read more
Articles
25.04.2022
What do France’s ATU reforms mean for manufa...

Introduction On 1 July 2021, France made changes to its long-standing Authorization for Temporary Us...

Read more
Articles
19.04.2022
Could Brexit lead to earlier access to medicines f...

Introduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...

Read more
Insider Insights
14.04.2022
Latest survey shows disparities in access

The study, compiled by IQVIA, covers 160 drugs, including 41 oncology drugs and 57 orphan drugs whic...

Read more
Articles
13.04.2022
How do you win the race to market? Our top conside...

Introduction Early Access Programs, also known as special access programs, give patients access to m...

Read more
News
06.04.2022
PMA Insights: Week 14

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
06.04.2022
Cancer report recommends access to new treatments

The report looks at how differences in cancer survival rates between the UK and other countries have...

Read more
Insider Insights
24.03.2022
“First of its kind” MAA leads to NICE approval

The draft final guidance reverses previous guidance issued in November 2021 rejecting the drug for r...

Read more
Insider Insights
21.03.2022
Early access agreement

Patients in England will be the first in Europe to have access to Takeda’s Exkivity (mobocertinib)...

Read more
Insider Insights
09.03.2022
First drug to receive positive recommendation from

Amgen’s Lumykras (sotorasib) has become the first active new technology to come through the Innova...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.